ArticleRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2025
Risk model derivation and clinical outcomes in COVID-19 pneumonia patients discharged from the emergency department.
Article in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and validate a clinical model to predict 30-day mortality in high-risk COVID-19 patients evaluated in the Emergency Department, and to evaluate outcomes in adults with COVID-19 pneumonia classified as low-risk by the model and discharged home.
methodsSecondary analysis of the COVID-19\_URG-HCSC registry at Hospital Clínico San Carlos (Madrid). Phase 1 (Feb-Apr 2020): derivation of a model in patients aged ≥18 years with probable or confirmed COVID-19 who were classified as high-risk at triage (age ≥55 years, baseline oxygen saturation <96% on arrival, or pulmonary infiltrates on chest radiograph). The primary outcome was 30-day all-cause mortality. Phase 2 (Sep 2020-May 2021): validation in adults with low-risk pneumonia discharged home and monitored by telephone. Primary outcomes were 30-day all-cause mortality, revisits, and hospitalization.
resultsOf 2,436 eligible patients in phase 1, age, oxygen saturation, renal function, LDH, CRP, platelet count and dementia were independent mortality predictors. The model showed excellent discrimination (AUC 0.918) and good calibration, and was implemented in a web-based tool. In phase 2, 565 patients with low-risk pneumonia were monitored; no deaths occurred at 30 days. Re-attendance was 8.0% and hospitalisation 12.6%, mainly for respiratory failure. All hospitalised patients were ultimately discharged home.
conclusionsThe PrediCOVID model provides accurate risk stratification and, when combined with telemonitoring, enables safe early discharges while reducing hospital burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.